About Regrow
Regrow is a company based in Mumbai (India) founded in 2009 by Bhavna Yashwant Sanghavi and Yash Sanghavi. It operates as a HealthTech and Professional Services. Regrow has raised $2.84 million across 9 funding rounds from investors including Satyan Pharmaceuticals, Ascus International and Richmond Asia Investment. The company has 95 employees as of April 08, 2024. Regrow offers products and services including OSSGROW, CARTIGROW, UREGROW, and BIOCELL. Regrow operates in a competitive market with competitors including Horizon Therapeutics, Osteal Therapeutics, ZetaGen, Angitia and Histogenics, among others.
- Headquarter Mumbai, India
- Employees 95 as on 08 Apr, 2024
- Founders Bhavna Yashwant Sanghavi, Yash Sanghavi
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Regrow Biosciences Pvt Ltd
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$2.31 M (USD)9.6as on Mar 31, 2023
-
Net Profit
-$313.02 K (USD)40.04as on Mar 31, 2023
-
EBITDA
$50.73 K (USD)-35.69as on Mar 31, 2023
-
Total Equity Funding
$2.84 M (USD)
in 9 rounds
-
Latest Funding Round
$89.36 K (USD), Seed
May 31, 2022
-
Investors
Satyan Pharmaceuticals
& 5 more
-
Employee Count
95
as on Apr 08, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Regrow
Regrow offers a comprehensive portfolio of products and services, including OSSGROW, CARTIGROW, UREGROW, and BIOCELL.
Bone cell therapy is provided for Avascular Necrosis treatment.
Cartilage cell therapy is offered for cartilage damage repair.
Epithelial cell therapy is used for urethral stricture treatment.
Umbilical cord blood banking is provided for therapeutic solutions.
Funding Insights of Regrow
Regrow has successfully raised a total of $2.84M across 9 strategic funding rounds. The most recent funding activity was a Seed round of $89.36 thousand completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Regrow
Regrow has secured backing from 6 investors, including institutional and angel investors. Prominent investors backing the company include Satyan Pharmaceuticals, Ascus International and Richmond Asia Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Satyan Pharmaceuticals operates as a contract manufacturing organization for pharmaceutical products.
|
Locked | Locked | Locked | |
|
Distributor of prescription & proprietary drugs and toiletries
|
Locked | Locked | Locked | |
|
Investments in Asian markets are facilitated by Richmond Asia Investment.
|
Locked | Locked | Locked |
Investor details for Regrow
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Regrow
Investment portfolio details for Regrow
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Regrow
Detailed financials for Regrow
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Regrow Comparisons
Peer comparison for Regrow
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Regrow
Regrow operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Osteal Therapeutics, ZetaGen, Angitia and Histogenics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for bone regeneration are developed.
|
|
| Locked | Locked | Locked |
Drugs for muscle, bone, and joint diseases are developed.
|
|
| Locked | Locked | Locked |
Restorative cell therapies for orthopedic diseases are developed.
|
|
| Locked | Locked | Locked |
Advanced cell separation technologies are developed for regenerative cell preparation.
|
Detailed competitors of Regrow
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Regrow
Complete news archive for Regrow
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regrow
Regrow was founded in 2009.
Regrow is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Yash Sanghavi is the current CEO of Regrow. They have also founded this company.
Regrow is a funded company, having raised a total of $2.84M across 9 funding rounds to date.
As of Apr 08, 2024, the latest employee count at Regrow is 95.
Annual revenue of Regrow is $2.31M as on Mar 31, 2023.
Regrow Biosciences is focused on developing tissue-targeted cell therapies for degenerative diseases. Solutions are provided in areas such as bone, cartilage, and epithelial regeneration. The company is recognized for pioneering therapies like OSSGROW for Avascular Necrosis, CARTIGROW for cartilage damage, and UREGROW for urethral stricture. Additionally, umbilical cord blood banking is offered through BIOCELL to address over 100 medical conditions. Operations are centered in the healthcare and biotechnology sector with an emphasis on innovative regenerative medicine.
Regrow's top competitors include Horizon Therapeutics, ZetaGen and Angitia.
Regrow offers OSSGROW, CARTIGROW, UREGROW, and BIOCELL.
Regrow has 6 investors. Key investors include Satyan Pharmaceuticals, Ascus International, Richmond Asia Investment, Satyan Finance & Investment Ltd, and Yash Sanghavi.
The valuation of Regrow is $13.01M as of May 2022.